Surgical Hemostats Market, By Product Type (Topical Thrombin-Based, Flowable, Collagen-Based, Oxidized Regenerated Cellulose-Based, Gelatin-Based, & Combination), Formulation (Matrix, Sponge, Powder), Application, End-use –Global Forecast (2024-2032)

Surgical Hemostats Market Size

Surgical Hemostats Market was valued at USD 3.3 billion in 2023 and is anticipated to grow at a CAGR of around 5.6% between 2024 and 2032. Surgical hemostats are medical devices designed to control bleeding during surgical procedures. They are used to promote hemostasis, which is the process of stopping or controlling bleeding. The increasing incidence of accidents and trauma cases on a global scale has significantly elevated the demand for efficient hemostasis solutions.
 

For instance, as per the World Health Organization (WHO), an estimated 4.4 million lives are annually lost worldwide due to injuries, encompassing both unintentional incidents and those linked to violence. This constitutes nearly 8% of all reported deaths. Particularly the fact that among individuals aged 5-29 years, three of the primary causes of mortality stem from injuries, specifically road traffic injuries, homicide, and suicide. Therefore, hemostatic products, designed to control and halt bleeding effectively, play a critical role in these emergency situations.
 

Furthermore, the increase in surgical procedures is propelled by a combination of factors, including heightened prevalence of chronic diseases, and remarkable advancements in medical technology. Moreover, the aging demographic contributes to a higher demand for surgeries related to joint replacements, cardiovascular issues, and cancer treatments. For instance, in 2023, approximately 70% of cardiothoracic surgeries involve patients aged 65 years or older, as indicated by statistics. Thus, the rise in chronic diseases necessitates surgical interventions for diagnosis and management, propel the market growth.

Surgical Hemostats Market Trends

Continuous progress in medical technology has spurred the evolution of increasingly sophisticated and efficient hemostasis products, which is estimated to reach 2.8 billion by 2032. The relentless pursuit of innovation has led to the creation of advanced adhesive, hemostasis and tissue sealing agents, revolutionizing the landscape of hemostatic procedures. For instance, in July 2023, Baxter International introduced its PerClot absorbable hemostatic powder in the U.S. PerClot stands out as a polysaccharide hemostat renowned for its convenient ready-to-use formulation, catering specifically to patients with intact coagulation. Distinguished by the inclusion of absorbable modified polymer particles, this hemostatic powder swiftly assimilates water from the blood, thereby accelerating the inherent physiological clotting cascade. Thus, these advanced hemostatic agents, offer quicker and more targeted control of bleeding and contribute to improve tissue adherence and reduced recovery time. Therefore, as the medical community continues to embrace these advancements, the surgical hemostats industry experiences sustained growth, propelled by the collective efforts to make surgical procedures more efficient, precise, and ultimately beneficial for patients.
 

Surgical Hemostats Market Analysis

The market by product type is categorized into topical thrombin-based hemostats, flowable hemostats, collagen-based hemostats, oxidized regenerated cellulose-based hemostats, gelatin-based hemostats, combination hemostats, and other product types. Oxidized regenerated cellulose-based hemostats segment held substantial revenue share in the surgical hemostats industry accounting for 19.9% market share in the year 2023.
 

• These hemostats are derived from cellulose, a natural polymer found in plant cell walls, and undergo a process of oxidation and regeneration to enhance their hemostatic properties. They are known for their effectiveness, biocompatibility, and absorbable nature.
   
• Their application in cardiac, orthopedic, and general surgeries, combined with a favorable safety profile, has contributed to their widespread adoption.
   
• Furthermore, the rising number of surgical procedures worldwide is amplifying the demand for reliable hemostatic agents, and continuous technological advancements in this field are projected to further enhance the performance and applicability of oxidized regenerated cellulose-based hemostats, thereby solidifying their position in the market.

Based on formulation, the market unfolds its segmentation, encompassing the domains of matrix & gel hemostats, sponge hemostats, sheet & pad hemostats, and powder hemostats. The matrix & gel hemostats segment garnered USD 1.3 billion revenue size in the year 2023.
 

• The matrix & gel hemostats segment holds substantial revenue primarily due to its ease of use and versatility, making it applicable across various surgical procedures.
   
• The efficiency in promoting rapid blood clotting, minimally invasive nature, and reduced complications compared to traditional methods contribute to widespread adoption. Continuous formulation innovation, aimed at improving efficacy and safety, further propels market growth.
   

Based on application, the surgical hemostats market unfolds its segmentation, encompassing the domains of general surgery, cardiovascular surgery, orthopedic surgery, gynecological surgery, neurosurgery, reconstructive surgery, and other applications. Orthopedic surgery segment held substantial revenue in the surgical hemostats industry accounting for USD 611.6 million in the year 2023.
 

• Orthopedic surgeries, marked by complexity and a heightened risk of bleeding, propel the demand for hemostatic agents. Surgical hemostats, renowned for their swift and efficient control of bleeding, play a pivotal role in meeting this requirement.
   
• For instance, in 2022, the World Health Organization (WHO) reported that the incidence of musculoskeletal conditions increases with age, impacting approximately 1.71 billion individuals globally. This encompasses prevalent conditions such as low back pain and osteoarthritis.
   
• Thus, the increasing prevalence of musculoskeletal disorders and a growing aging population base contributes to a surge in orthopedic surgeries, intensifying the need for hemostatic solutions, stimulate the market growth.
   

Based on end-use, the market unfolds its segmentation, encompassing the domains of clinics, hospitals, ambulatory surgical centers, and other end-users. Hospitals segment held substantial revenue share in the surgical hemostats market accounting for 47.9% market share in the year 2023.
 

• The surge in surgical procedures conducted within hospitals, encompassing emergency room (ER) and minimally invasive surgeries, has significantly bolstered the demand for surgical hemostats.
   
• Moreover, technological advancements in hemostatic technologies have played a pivotal role by providing products with enhanced efficacy and safety profiles, making them particularly attractive in hospital settings.
   
• The cost-effectiveness and efficiency of surgical hemostats have further facilitated their widespread adoption in hospital, aligning with the imperative of delivering high-quality care.
   
• Additionally, the prevailing trend towards outpatient care, coupled with patients' preferences for the convenience and personalized experience offered by healthcare settings, has been instrumental in elevating the prominence of the hospitals segment within the surgical hemostats industry.

U.S. market accounted for USD 1.1 billion revenue size in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• U.S. has taken a leading role in the surgical hemostats industry, stimulated by a combination of advanced healthcare infrastructure, a high incidence of chronic diseases, continuous technological innovations, an aging population base, stringent regulatory standards, robust research and development activities, substantial healthcare expenditure, and strategic collaborations.
   
• The region's well-established healthcare system facilitates the adoption of sophisticated surgical procedures that often require the use of hemostasis products.
   
• Moreover, the prevalence of chronic diseases, particularly cardiovascular disorders, contributes to a sustained demand for these products. For instance, in 2020, as per the American Heart Association, approximately 928,741 people died in the U.S. owing to some form of cardiovascular disease.
   
• Furthermore, the region’s commitment to research and development, coupled with strategic partnerships, ensures the ongoing advancement and commercialization of innovative hemostasis solutions, reinforcing its prominent position in the global market.
   

Surgical Hemostats Market Share

The surgical hemostats industry is consolidated, with key players including Medtronic Plc, Ethicon, Inc. (Johnson & Johnson), Baxter International Inc., Teleflex Corporation, Pfizer, Inc., and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in September 2022, Medtronic plc announced U.S. FDA clearance for its Nexpowder endoscopic hemostasis system. This system is developed by Nextbiomedical CO., LTD and distributed by Medtronic. Additionally, this system is designed to address upper gastrointestinal nonvariceal bleeding, a common medical issue that accounts for a significant portion of acute gastrointestinal (GI) bleeding cases. Such product approvals help companies to strengthen its product offerings and generate significant revenue.
 

Surgical Hemostats Market Companies

Some of the eminent market participants operating in the surgical hemostats industry include:

• Becton, Dickinson and Company    
• Medtronic plc
• Teleflex Corporation
• Baxter International Inc.
• B. Braun Melsungen AG
• Pfizer, Inc.
• Ethicon, Inc. (Johnson & Johnson)
• Stryker Corporation
• CuraMedical BV       
• Gelita Medical GmbH
• Integra LifeSciences
• Marine Polymer Technologies, Inc
• Hemostasis LLC
   

Surgical Hemostats Devices Industry News

• In August 2023, the Teleflex Corporation received U.S. FDA clearance for its QuikClot Control+ Hemostatic Device. This device helps surgeons to control bleeding during cardiac surgical procedures. Therefore, approval of this product helped the company to enhance its product offerings.
   
• In November 2023, Ethicon announced CE mark approval for its adjunctive hemostat solution ETHIZIA. ETHIZIA Hemostatic Sealing Patch is used for disrupting bleeding on internal organs, except neurological and cardiovascular. This helped company to strengthen its product portfolio.
   

Surgical hemostats market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Topical thrombin-based hemostats
• Flowable hemostats
• Collagen-based hemostats
• Oxidized regenerated cellulose-based hemostats
• Gelatin-based hemostats
• Combination hemostats
• Other product types

Market, By Formulation

• Matrix & gel hemostats
• Sponge hemostats
• Sheet & pad hemostats
• Powder hemostats

Market, By Application

• General surgery
• Cardiovascular surgery
• Orthopedic surgery
• Gynecological surgery
• Neurosurgery
• Reconstructive surgery
• Other applications

Market, By End-use

• Clinics
• Hospitals
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa